Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus

Modern Pathology

Volumn 22, Issue 2, 2009, Pages 252-260

  Tzao, Ching ^a   Tung, Ho Jui ^b   Jin, Jong Shiaw ^a   Sun, Guang Huan ^a   Hsu, Han Shui ^c   Chen, Ban Hen ^a   Yu, Cheng Ping ^a   Lee, Shih Chun ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Esophageal squamous cell carcinoma; Histone modification; Prognosis

Indexed keywords

ARGININE; HISTONE H3; HISTONE H4; LYSINE; PARAFFIN;

ACETYLATION; ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DNA METHYLATION; DNA MODIFICATION; EARLY CANCER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION; UNIVARIATE ANALYSIS;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; LYSINE; MALE; METHYLATION; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN PROCESSING, POST-TRANSLATIONAL; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 59149096527     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.172     Document Type: Article

References (29)

1. Layke JC, Lopez PP. Esophageal cancer: a review and update. Am Fam Physician 2006;73:2187-2194.
2. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005;16:1740-1748.
3. Lau CL, Moore MB, Brooks KR, D'Amico TA, Harpole Jr DH. Molecular staging of lung and esophageal cancer. Surg Clin North Am 2002;82:497-523.
4. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004;18:2315-2335.
5. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005;14(Spec No 1):R85-R92.
6. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-3993.
7. Esteller M. The necessity of a human epigenome project. Carcinogenesis 2006;27:1121-1125.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
9. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-1080.
10. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-1266.
11. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25:4358-4364.
12. Greene FL. AJCC Cancer Staging Manual 6th edn. American Joint Committee on Cancer, American Cancer Society: New York, 2002;93-94.
13. Cha TL, Zhou BP, Xia W, et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005;310:306-310.
14. Kaplan ELMP, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
15. The Lifetest Procedure I. SAS Technical Report: P-179, Additional SAS/STAT Procedures, Release 6.03. SAS Institute: Cary, NC, 1988, pp 49-90.
16. D'Amico TA. Molecular staging and the selection of therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2005;17:180-185.
17. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
18. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-1128.
19. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2007;96(Suppl):R26-R30.
20. Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 2007;97:1-5.
21. Abbosh PH, Montgomery JS, Starkey JA, et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 2006;66:5582-5591.
22. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 premarks genes for de novo methylation in cancer. Nat Genet 2007;39:232-236.
23. Brock MV, Herman JG, Baylin SB. Cancer as a manifestation of aberrant chromatin structure. Cancer J 2007;13:3-8.
24. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
25. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11611.
26. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-1063.
27. Wei Y, Xia W, Zhang Z, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701-706.
28. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-178.
29. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 2005;6:838-849.